Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNFRSF1A | P19438 | 13/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
| ▸ | ACLY | P53396 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6040544 | 1.00 | TNFRSF1A (0.67) | TNFRSF1AMEN1LMNAGAAMAPT | |
| SCHEMBL6040921 | 0.86 | TNFRSF1A (0.71) | TNFRSF1AMAPTSMN1; SMN2ABCG2DPP4 | |
| SCHEMBL6040923 | 0.86 | TNFRSF1A (0.71) | TNFRSF1AMAPTSMN1; SMN2ABCG2DPP4 | |
| SCHEMBL6040561 | 0.85 | TNFRSF1A (0.75) | TNFRSF1AMEN1LMNAGAAMAPT | |
| SCHEMBL6040565 | 0.85 | TNFRSF1A (0.75) | TNFRSF1AMEN1LMNAGAAMAPT | |
| SCHEMBL5565351 | 0.84 | MAPT (0.47) | TNFRSF1AMEN1LMNAGAAMAPT | |
| SCHEMBL5560103 | 0.84 | MAPT (0.47) | TNFRSF1AMEN1LMNAGAAMAPT | |
| SCHEMBL5560107 | 0.84 | MAPT (0.47) | TNFRSF1AMEN1LMNAGAAMAPT | |
| SCHEMBL6040522 | 0.83 | TNFRSF1A (0.80) | TNFRSF1AMEN1LMNAMAPTKMT2A | |
| SCHEMBL6040517 | 0.83 | TNFRSF1A (0.80) | TNFRSF1AMEN1LMNAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060189549-A1 | Chalcone derivatives and their use to treat diseases | NI LIMING | 2006-08-24 | — | — | US | disclosed |
| US-7094801-B2 | Chalcone derivatives and their use to treat diseases | ATHEROGENICS, INC. (US) | 2006-08-22 | — | — | US | disclosed |
| EP-1465854-A4 | CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES | ATHEROGENICS INC (US) | 2005-06-08 | — | — | EP | disclosed |
| EP-1465854-A2 | CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES | Atherogenics, Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040048858-A1 | Chalcone derivatives and their use to treat diseases | CRABTREE ACQUISITION CO, LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003053368-A2 | CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES | ATHEROGENICS, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189549-A1 | Chalcone derivatives and their use to treat diseases | CYP46A1, HSD17B7, CYP11B2 | TNFRSF1A 3846/4885MEN1 1759/4885LMNA 1624/4885 |
| US-20040048858-A1 | Chalcone derivatives and their use to treat diseases | CYP46A1, CYP11B1, HSD17B7 | TNFRSF1A 3877/4885MEN1 1050/4885LMNA 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.